Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation.
Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the potential for neuropsychiatric events. The costs associated with varenicline are offset by direct savings associated with the reduction in smoking-related diseases. Indeed, despite their limitations, available pharmacoeconomic analyses from numerous countries support the use of varenicline for 12 or 24 weeks as a cost-effective treatment relative to other smoking cessation therapies in smokers who wish to quit smoking. For example, in modelled cost-effectiveness analyses conducted from a healthcare payer perspective, 12 weeks' treatment with varenicline consistently dominated bupropion sustained release and nicotine replacement therapy, and was dominant over, or considered cost effective relative to, unaided cessation, brief counselling or nortriptyline, with regard to the incremental costs per quality-adjusted life-year or life-year gained.
Keating
Gillian M
GM
Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz
Lyseng-Williamson
Katherine A
KA
D001552:Benzazepines; D003362:Cost-Benefit Analysis; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D018722:Nicotinic Agonists / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D011810:Quinoxalines; D016540:Smoking Cessation / Q000191:economics* / Q000379:methods; D014029:Tobacco Use Disorder / Q000188:drug therapy / Q000191:economics*; D000068580:Varenicline
D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D000068580:Varenicline
Expert Rev Pharmacoecon Outcomes Res. 2009 Jun;9(3):257-64
19527098
Clin Drug Investig. 2009;29(10):655-65
19715382
Pharmacoeconomics. 2008;26(6):497-511
18489200
Clin Ther. 2007 Jun;29(6):1040-56
17692720
Vasc Health Risk Manag. 2008;4(4):837-45
19066000
Pharmacotherapy. 2007 Nov;27(11):1550-7
17963463
BMJ. 2004 Jan 24;328(7433):217-9
14739193
Curr Med Res Opin. 2008 Jan;24(1):51-61
18021492
Am J Health Behav. 2008 Nov-Dec;32(6):664-75
18442345
JAMA. 2006 Jul 5;296(1):47-55
16820546
MMWR Morb Mortal Wkly Rep. 2008 Nov 14;57(45):1226-8
19008791
Respir Med. 2008 May;102(5):699-710
18289839
Curr Med Res Opin. 2010 Mar;26(3):549-60
20050814
Prev Chronic Dis. 2009 Jul;6(3):A84
19527585
Tob Control. 2004 Dec;13(4):388-95
15564623
JAMA. 2006 Jul 5;296(1):64-71
16820548
J Eval Clin Pract. 2009 Jun;15(3):478-85
19536915
Value Health. 2010 Mar-Apr;13(2):209-14
19912599
An Med Interna. 2008 Jul;25(7):342-8
19295994
Pharmacoeconomics. 2010;28(3):231-54
20108995
Eur J Public Health. 2009 Dec;19(6):650-4
19491286
Am J Med. 2008 Apr;121(4 Suppl 1):S32-42
18342165
Thorax. 2008 Aug;63(8):717-24
18263663
Pharmacoeconomics. 2009;27(3):247-61
19354344
JAMA. 2006 Jul 5;296(1):56-63
16820547
Manag Care Interface. 2007 Oct;20(10):18-25
18405203